08:52 AM EDT, 09/09/2024 (MT Newswires) -- Health care stocks were edging higher premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) up 0.4% and the iShares Biotechnology ETF (IBB) gaining 0.5%.

Summit Therapeutics ( SMMT ) shares were up past 30% after the company said data from the primary analysis of the phase 3 HARMONi-2 trial showed that ivonescimab monotherapy has a statistically significant improvement in progression-free survival compared with pembrolizumab monotherapy as a first-line treatment in patients with non-small cell lung cancer.